Assessment of survival benefit from sentinel node biopsy for melanoma: a systematic review and meta-analysis - PubMed
4 days ago
- #sentinel node biopsy
- #melanoma
- #meta-analysis
- Sentinel node biopsy (SNB) for melanoma patients shows a significant reduction in the risk of death from melanoma.
- Meta-analysis of 13 studies (40,287 participants) found a hazard ratio (HR) of 0.86 (95% CI 0.81-0.92, p<0.0001) for reduced risk of death from melanoma with SNB.
- Five studies (27,540 participants) reported a 5-year risk of death from melanoma with HR 0.84 (95% CI 0.78-0.90, p<0.0001).
- Two studies reported a 10-year risk of death from melanoma with HR 0.87 (95% CI 0.71-1.06, p=0.17) but with greater heterogeneity (I² 41%).
- Nine studies (11,625 participants) showed a reduced risk of recurrence with HR 0.71 (95% CI 0.66-0.76, p<0.0001).
- The findings are consistent with the only published randomized controlled trial, indicating true survival and recurrence benefits from SNB.
- The study was registered with PROSPERO (CRD4203494674) and involved searches of Medline, Embase, Cochrane CENTRAL, and ClinicalTrials.gov.
- Conflict of interest disclosures include honoraria, research grants, and advisory board participation from various pharmaceutical companies.